Precision Biologics announces that Massimo Fantini PhD, our Director of Research and Development, will deliver...
A poster will be presented in person at the American Association for Cancer Research (AACR)...
Precision Biologics, Inc. publishes data and analysis from recent First-In-Human Phase 1 Clinical Trial With...
Dr. Philip M. Arlen, President and CEO, Precision Biologics, gives keynote address entitled “Preclinical/Clinical Development...
Society for the Immunotherapy of Cancer 2022 Annual Meeting, November 8 – 12, Boston, MA,...
Dr. Philip M. Arlen gives presentation “Preclinical/Clinical Development of a Neo-Epitope Targeted Monoclonal Antibody for...
Precision Biologics, Inc. and our collaborators at the NCI deliver a poster presentation at the...
Dr. Philip M. Arlen gives Immunotherapy Section Opening Keynote at Festival of Biologics 2022, San...
Dr. Philip M. Arlen gives scientific presentation at Biomarkers UK: In-Person, Day 1 – November...
The Phase 2 Clinical Trial with a safety lead in, combining Precision Biologics monoclonal antibody...